Additionally, in a mouse model of PI3K-driven vascular malformation with EC-specific-Pik3caH1047R expressions, miransertib not only prevented disease progression but also fully regressed established vascular malformations, indicating its promise as a therapeutic strategy for both PIK3CA and TEK-mutant vascular malformations [155]. The gene discussed is PIK3CB; the disease is vascular malformation.